Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Metastatic melanoma treatments like targeted therapy and immunotherapy show promise but are limited by therapeutic resistance.
• A persistent subpopulation of melanoma cells contributes to resistance, even after initial treatment response, but the underlying mechanisms are unclear.

Purpose of the Study:

• To propose a novel model explaining the development of therapeutic resistance in melanoma.
• To elucidate the role of dynamic single-cell protein expression and population-level cell state changes in resistance.
• To identify key signaling pathways and phases involved in melanoma resistance.

Main Methods:

• Conceptual modeling focusing on dynamic protein expression fluctuations at the single-cell level.
• Analysis of longitudinal cell-population state reshaping.
• Investigation of pivotal signaling pathways: microphthalmia-associated transcription factor (MITF) and Interferon gamma (IFNγ).

Main Results:

• A model is proposed where dynamic protein expression and cell state changes drive therapeutic resistance.
• Melanoma resistance development is described in three phases: early survival, senescence reversal, and establishment of irreversible resistance.
• The model integrates MITF and IFNγ signaling pathways to explain evolving melanoma cell states.

Conclusions:

• Dynamic cellular processes at single-cell and population levels are crucial for understanding melanoma therapeutic resistance.
• The proposed three-phase model provides a framework for resistance development.
• Future research should focus on translational studies and therapeutic strategies informed by this dynamic resistance model.